Education
About Us
Working with TipRanks
Follow Us
Novolog (Pharm UP 1966) Ltd. (IL:NVLG)
:NVLG
NVLG Stock Chart & Stats
126.20
>-0.01(-0.31%)
At close: 4:00 PM EST
126.20
>-0.01(-0.31%)
Day’s Range― - ―
52-Week Range114.10 - 170.49
Previous CloseN/A
Volume351.22K
Average Volume (3M)641.09K
Market Cap
₪602.83M
Enterprise Value590.15M
Total Cash (Recent Filing)₪222.20M
Total Debt (Recent Filing)₪209.52M
Price to Earnings (P/E)48.6
Beta0.67
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.05%
Share Statistics
EPS (TTM)0.80
Shares Outstanding510,874,760
10 Day Avg. Volume285,794
30 Day Avg. Volume641,093
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)2.51
Price to Sales (P/S)0.46
P/FCF Ratio9.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent revenue growth indicates strong market demand and effective product adoption, supporting long-term business expansion.
Stable Balance SheetA stable balance sheet with manageable leverage supports financial resilience and the ability to invest in growth opportunities.
Cash GenerationImproved cash generation enhances financial flexibility, allowing for reinvestment in R&D and potential strategic acquisitions.
Bears Say
Profitability ChallengesDeclining profitability margins suggest operational inefficiencies, which may hinder long-term financial performance if not addressed.
Cash Flow EfficiencyReduced cash flow efficiency can strain liquidity and limit the company's ability to fund operations and growth initiatives.
Return On EquityA decline in return on equity indicates less effective use of shareholder funds, potentially impacting investor confidence and capital raising.
Novolog News
NVLG FAQ
What was Novolog (Pharm UP 1966) Ltd.’s price range in the past 12 months?
Novolog (Pharm UP 1966) Ltd. lowest stock price was 114.10 and its highest was 170.49 in the past 12 months.
What is Novolog (Pharm UP 1966) Ltd.’s market cap?
Novolog (Pharm UP 1966) Ltd.’s market cap is ₪602.83M.
When is Novolog (Pharm UP 1966) Ltd.’s upcoming earnings report date?
Novolog (Pharm UP 1966) Ltd.’s upcoming earnings report date is May 20, 2026 which is in 84 days.
How were Novolog (Pharm UP 1966) Ltd.’s earnings last quarter?
Novolog (Pharm UP 1966) Ltd. released its earnings results on Nov 12, 2025. The company reported 0.8 earnings per share for the quarter, beating the consensus estimate of N/A by 0.8.
Is Novolog (Pharm UP 1966) Ltd. overvalued?
According to Wall Street analysts Novolog (Pharm UP 1966) Ltd.’s price is currently Overvalued.
Does Novolog (Pharm UP 1966) Ltd. pay dividends?
Novolog (Pharm UP 1966) Ltd. pays a Quarterly dividend of 1.957 which represents an annual dividend yield of 3.05%. See more information on Novolog (Pharm UP 1966) Ltd. dividends here
What is Novolog (Pharm UP 1966) Ltd.’s EPS estimate?
Novolog (Pharm UP 1966) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novolog (Pharm UP 1966) Ltd. have?
Novolog (Pharm UP 1966) Ltd. has 510,874,760 shares outstanding.
What happened to Novolog (Pharm UP 1966) Ltd.’s price movement after its last earnings report?
Novolog (Pharm UP 1966) Ltd. reported an EPS of 0.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Novolog (Pharm UP 1966) Ltd.?
Currently, no hedge funds are holding shares in IL:NVLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novolog (Pharm UP 1966) Ltd.
Novolog (NVLG) is a biotechnology company specializing in the development and commercialization of innovative pharmaceutical products, primarily focusing on treatments for diabetes and other metabolic disorders. The company operates in the healthcare sector, leveraging advanced research to create effective therapies that improve patient outcomes. Novolog’s core products include insulin formulations and delivery systems designed to enhance the management of blood glucose levels in diabetic patients.